The invention is directed to novel 9-hydroxyalkylamino-, 9-alkoxyalkylamino-1- nitroacridine derivatives. Methods of preparation, pharmaceutical compositions comprising said derivatives and their medical uses are also encompassed by this invention.
The invention is directed to 1-nitroacridine derivative(s)/tumor inhibitor(s) compositions as well as methods for using said compositions for inhibiting or preventing tumor growth, particularly, prostate cancer cell growth and metastases.